Adenosine A2A receptor agonists with potent antiplatelet activity

被引:18
作者
Fuentes, Eduardo [1 ,2 ]
Fuentes, Manuel [1 ]
Caballero, Julio [3 ]
Palomo, Ivan [1 ]
Hinz, Sonja [4 ]
El-Tayeb, Ali [4 ]
Mueller, Christa E. [4 ]
机构
[1] Univ Talca, Platelet Res Lab, Dept Clin Biochem & Immunohematol, Fac Hlth Sci,Interdisciplinary Excellence Res Pro, Talca, Chile
[2] Univ Talca, Nucleo Cient Multidisciplinario, Talca, Chile
[3] Univ Talca, CBSM, Talca, Chile
[4] Univ Bonn, PharmaCtr Bonn, Pharmaceut Inst, Pharmaceut Chem 1, Bonn, Germany
关键词
Adenosine A(2A) receptor; antiplatelet activity; cAMP; docking; platelet; radioligand binding; PERCUTANEOUS CORONARY INTERVENTION; RESIDUAL PLATELET REACTIVITY; CLOPIDOGREL; THERAPY; ANTAGONISTS; DRUGS; DESENSITIZATION; CLASSIFICATION; IDENTIFICATION; DERIVATIVES;
D O I
10.1080/09537104.2017.1306043
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Selected adenosine A(2A) receptor agonists (PSB-15826, PSB-12404, and PSB-16301) have been evaluated as new antiplatelet agents. In addition, radioligand-binding studies and receptor-docking experiments were performed in order to explain their differential biological effects on a molecular level. Among the tested adenosine derivatives, PSB-15826 was the most potent compound to inhibit platelet aggregation (EC50 0.32 +/- 0.05 mu mol/L) and platelet P-selectin cell-surface localization (EC50 0.062 +/- 0.2 mu mol/L), and to increase intraplatelets cAMP levels (EC50 0.24 +/- 0.01 mu mol/L). The compound was more active than CGS21680 (EC50 0.97 +/- 0.07 mu mol/L) and equipotent to NECA (EC50 0.31 +/- 0.05 mu mol/L) in platelet aggregation induced by ADP. In contrast to the results from cAMP assays, K-i values determined in radioligand-binding studies were not predictive of the A(2A) agonists' antiplatelet activity. Docking studies revealed the key molecular determinants of this new family of adenosine A(2A) receptor agonists: differences in activities are related to -stacking interactions between the ligands and the residue His264 in the extracellular loop of the adenosine A(2A) receptor which may result in increased residence times. In conclusion, these results provide an improved understanding of the requirements of antiplatelet adenosine A(2A) receptor agonists.
引用
收藏
页码:292 / 300
页数:9
相关论文
共 52 条
[11]   Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists [J].
El-Tayeb, Ali ;
Michael, Sebastian ;
Abdelrahman, Aliaa ;
Behrenswerth, Andrea ;
Gollos, Sabrina ;
Nieber, Karen ;
Mueller, Christa E. .
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (12) :890-895
[12]   Nucleoside-5′-monophosphates as Prodrugs of Adenosine A2A Receptor Agonists Activated by ecto-5′-Nucleotidase [J].
El-Tayeb, Ali ;
Iqbal, Jamshed ;
Behrenswerth, Andrea ;
Romio, Michael ;
Schneider, Marion ;
Zimmermann, Herbert ;
Schrader, Juergen ;
Mueller, Christa E. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (23) :7669-7677
[13]   Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations [J].
Ellis, Kyle J. ;
Stouffer, George A. ;
McLeod, Howard L. ;
Lee, Craig R. .
PHARMACOGENOMICS, 2009, 10 (11) :1799-1817
[14]  
Fotheringham AS, 1999, GEOGR ANAL, V31, P340
[15]   Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike [J].
Franchi, Francesco ;
Rollini, Fabiana ;
Park, Yongwhi ;
Angiolillo, Dominick J. .
PROGRESS IN CARDIOVASCULAR DISEASES, 2015, 58 (03) :267-277
[16]   International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors-An Update [J].
Fredholm, Bertil B. ;
IJzerman, Adriaan P. ;
Jacobson, Kenneth A. ;
Linden, Joel ;
Mueller, Christa E. .
PHARMACOLOGICAL REVIEWS, 2011, 63 (01) :1-34
[17]   Inhibition of Platelet Activation and Thrombus Formation by Adenosine and Inosine: Studies on Their Relative Contribution and Molecular Modeling [J].
Fuentes, Eduardo ;
Pereira, Jaime ;
Mezzano, Diego ;
Alarcon, Marcelo ;
Caballero, Julio ;
Palomo, Ivan .
PLOS ONE, 2014, 9 (11)
[18]   Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk [J].
Fuentes, Eduardo ;
Palomo, Ivan .
THROMBOSIS RESEARCH, 2014, 134 (02) :221-226
[19]   Chlorogenic Acid Inhibits Human Platelet Activation and Thrombus Formation [J].
Fuentes, Eduardo ;
Caballero, Julio ;
Alarcon, Marcelo ;
Rojas, Armando ;
Palomo, Ivan .
PLOS ONE, 2014, 9 (03)
[20]   Protective mechanisms of adenosine 5′-monophosphate in platelet activation and thrombus formation [J].
Fuentes, Eduardo ;
Badimon, Lina ;
Caballero, Julio ;
Padro, Teresa ;
Vilahur, Gemma ;
Alarcon, Marcelo ;
Perez, Pablo ;
Palomo, Ivan .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (03) :491-507